Pancreatic cancer is a growing health concern, now the fourth leading cause of cancer death in Europe, with incidence rates steadily climbing.Following World Pancreatic Cancer Day on November 20th, new research offers a glimmer of hope in the fight against this aggressive disease, which currently has a dismal 11% five-year survival rate. This report details ongoing investigations into early detection methods and novel therapies, spearheaded by organizations like the Fondation ARC, aiming to improve outcomes for patients facing this challenging diagnosis.
Pancreatic cancer is now the fourth leading cause of cancer death in Europe, and awareness of the disease was raised on World Pancreatic Cancer Day, observed on November 20th. In 2023, approximately 16,000 people in France were diagnosed with this aggressive cancer, a figure that reflects a concerning trend. Incidence rates have been steadily increasing, rising by 1.6% annually among men and 2.1% annually among women between 2010 and 2023.
Low Survival Rates Highlight Need for Early Detection
One of the major challenges in combating pancreatic cancer is that it’s often diagnosed at a late stage, after the tumor has spread beyond the pancreas. This delay is due, in part, to the fact that early symptoms are often vague and can be attributed to other, less serious conditions, hindering timely diagnosis.
Unfortunately, in 80 to 90% of cases, the cancer is discovered when surgery – currently the only potentially curative treatment – is no longer an option. The Fondation ARC contre le cancer notes that treatment then relies on intensive chemotherapy, which is often insufficient to control the disease. This underscores the critical need for improved diagnostic tools and more effective therapies.
“There is an urgent need to develop new diagnostic and therapeutic approaches.”
The five-year survival rate for pancreatic cancer remains low, at just 11%.
Promising Research Offers Hope
With incidence rates climbing and limited treatment options, projections indicate that pancreatic cancer could become the second leading cause of cancer-related deaths in Europe and the United States by 2030. To address this growing crisis, the Fondation ARC launched the PANCREAS project in 2022. The initiative aims to support innovative research focused on early diagnosis, new therapies for patients who are not candidates for surgery, and targeting the tumor microenvironment to overcome treatment resistance.
The foundation is currently highlighting three key research projects:
- Overcoming Resistance to Chemotherapy and Immunotherapy: Researchers at the Centre Georges François Leclerc in Dijon are investigating whether blocking the production of interleukin-1 (IL-1), a protein produced by the immune system, could restore the effectiveness of chemotherapy and immunotherapy treatments. Their work explores the possibility that IL-1 allows tumor cells to shield themselves from these therapies.
Recognizing the Warning Signs
Early detection relies on awareness of potential symptoms. The Léon-Bérard Cancer Centre in Lyon lists the following signs that warrant medical attention:
- Jaundice;
- Abdominal pain;
- Mid-back pain;
- New-onset diabetes;
- Blood clots;
- Changes in bowel habits;
- Unexplained weight loss;
- Nausea;
- Symptoms of depression.
With Destination Santé
Personalize your news by adding your cities and media as favorites with Mon Actu.
